Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Michaela Koehm¹, Michael Hofmann², Rasmus Lüthje², Matthew McIntosh³, Varghese Abraham³, Cem Gabay⁴, Arthur Kavanaugh⁵, Harald Burkhardt⁶ and Frank Behrens⁶, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ³Genentech, San Francisco, CA, ⁴SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁵Medicine, University of California, San Diego, La Jolla, CA, ⁶Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
Abstract Number: 2608 • 2016 ACR/ARHP Annual Meeting
Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab
Atsushi Noguchi^1,2, Shinsuke Yasuda¹, Ryo Hisada¹, Kazumasa Ohmura¹, Sanae Shimamura¹, Yuka Shimizu¹, Masaru Kato¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Miho Suzuki³, Yoshihiro Matsumoto⁴ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³Product research department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ⁴Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: Consecutive RA patients who initiated treatment with TCZ between December 2013 and September 2015 were enrolled in our prospective study. All patients met 2010…
Abstract Number: 2611 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Seoyoung C. Kim¹, Daniel H. Solomon¹, James R. Rogers¹, Sara Gale², Micki Klearman², Khaled Sarsour² and Sebastian Schneeweiss¹, ¹Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at elevated risk for cardiovascular (CV) disease. Patients using tocilizumab (TCZ) may experience increased serum lipid levels. It…
Abstract Number: 2620 • 2016 ACR/ARHP Annual Meeting
Retrospective Analysis for Determining the Signs and Symptoms of Infections before They Become Serious in Tocilizumab-Treated RA Patients Using a Postmarketing Adverse Events Reporting Database
Tatsuya Atsumi¹, Yoshiaki Ando², Yukiko Hayashi², Shinichi Matsuda², Riwa Tanaka², Nobuhiro Takagi² and Ayako Nakasone², ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Chugai Pharmaceutical Co. Ltd., Tokyo, Japan
Background/Purpose: Given that tocilizumab (TCZ) directly inhibits IL-6 signaling and strongly suppresses the inflammatory reaction, there is concern that the signs and symptoms associated with…
Abstract Number: 60 • 2016 ACR/ARHP Annual Meeting
A Single Nucleotide Polymorphism of IL6-Receptor Is Associated with Response to Tocilizumab in Rheumatoid Arthritis: Results from Toci and ROC Studies
Cécile Luxembourger¹, Adeline Ruyssen-Witrand², Yannick Degboé³, Alain G. Cantagrel¹, Arnaud CONSTANTIN⁴, Philippe Gaudin⁵, Christian Jorgensen⁶, Jean-Francis Maillefert⁷, Hubert Marotte Sr.⁸, Delphine Nigon⁹, Daniel Wendling¹⁰, Jacques-Eric Gottenberg¹¹ and Yves-marie Pers¹², ¹Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ²Rheumatology Center, Purpan University Hospital, Toulouse, France, ³Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, ⁴Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁵Rheumatology, Grenoble University Hospital, France, Grenoble, France, ⁶Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, ⁷Rheumatology, University Hospital, Dijon, France, ⁸CHU de St Etienne, Service de rhumatologie, St Etienne, France, ⁹CHU Purpan, Toulouse, France, ¹⁰Rheumatology, Besançon university hospital, Besançon, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²coordination RIC SUD, Montpellier, France
Background/Purpose: Biological agents (boDMARDs) have modified the therapeutic management of patients with rheumatoid arthritis (RA). However, boDMARDs can induce sustained remission in only 30% of…
Abstract Number: 630 • 2016 ACR/ARHP Annual Meeting
Strategies for Biological Drug Quantification in Biological Drug Immune Responses
Michael Kruse Meyer^1,2, Marlene Andersen^1,3, Troels Vindbæk Stausbo⁴, Tue Bjerg Bennike^4,5, Grethe Neumann Andersen^1,6 and Allan Stensballe^3,4, ¹Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, ²Laboratory for Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ³Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, ⁴Laboratory of Medical Mass Spectrometry, Aalborg University, Aalborg, Denmark, ⁵Research Unit for Molecular Diagnostic and Clinical Research, Harvard Medical School, Boston, MA, ⁶Center for Clinical Science, Aalborg University, Hjørring, Denmark
Background/Purpose: The development of the biological DMARDs has benefitted patients, who previously had no treatment options. Currently no method for stratifying patients to these drugs…
Abstract Number: 1495 • 2016 ACR/ARHP Annual Meeting
Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project
Maria Carmen Garcia-Gomez¹, Maria Auxiliadora Martin², Santos Castañeda³, Fernando Sánchez-Alonso⁴, Miren Uriarte Ecenarro⁵, Carlos González-Juanatey⁶, Romera-Baures Monserrat⁷, Santos-Rey Jose⁸, Jose A Pinto-Tasende⁹, Estefania QuesadaMasachs¹⁰, Jesús Tornero¹¹, Olga Martínez González¹², Tatiana Cobo-Ibáñez¹³, Eugenio Chamizo Carmona¹⁴, Sara Manrique-Arija¹⁵, Dolores Fábregas-Canales¹⁶, Federico Díaz-González¹⁷, Javier Llorca¹⁸, Miguel Angel González-Gay¹⁹ and CARMA Collaborative Group, ¹Rheumatology, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ⁴Research Unit of Spanish Society of Rheumatology, Madrid, Spain, ⁵Donostia University Hospital, San Sebastian, Spain, ⁶Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁷Rheumatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain, ⁸Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ⁹Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, ¹⁰Rheumatology, Hospital Universitari Vall d’Hebron, Barcelona, Spain, ¹¹Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹²Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ¹³Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁴Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁵Rheumatology, Hospital Carlos Haya, Malaga, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Barbastro (Huesca), Spain, ¹⁷Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ¹⁸Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain
Background/Purpose: Plasma concentrations of lipoprotein (a) [Lp(a)], a lipoprotein with proatherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have…
Abstract Number: 1581 • 2016 ACR/ARHP Annual Meeting
The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Maria A. Ortiz², Patricia Moya³, M. Victoria Hernández⁴, Delia Reina⁵, Ivan Castellvi⁶, Juan Jose De Agustin⁷, Diana De La Fuente⁸, Hector Corominas^9,10, Raimon Sanmarti¹¹, Josep Maria De Llobet Zubiaga¹ and Silvia Vidal², ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Institut de Recerca Sant Pau, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁶Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁷Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ⁸Rheumatology, Hospital de Viladecans, Barcelona, Spain, ⁹Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ¹⁰Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, ¹¹Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain
Background/Purpose: Several predictors of response to tocilizumab have been described. They include a low HAQ, high baseline CRP or NK levels and certain IL-6R polymorphisms.…
Abstract Number: 1592 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group, Phase III Study of Shortening the Dosing Interval of Subcutaneous Tocilizumab Monotherapy in RA Patients with an Inadequate Response to Subcutaneous Tocilizumab Every Other Week
Atsushi Ogata¹, Nobuhiro Takagi², Hiroko Miwa³ and the MRA231JP study group, ¹Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine and NTT West Osaka Hospital, Osaka, Japan, ²Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, ³Chugai Pharmaceutical Co. Ltd, Tokyo, Japan
Background/Purpose: The non-inferiority of subcutaneous tocilizumab (TCZ-SC) monotherapy every 2 weeks (q2w) to intravenous TCZ monotherapy every 4 weeks was demonstrated in Japanese patients with…
Abstract Number: 1596 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors
Leslie R. Harrold^1,2, George W. Reed^1,2, Jennie Best³, Steve Zlotnick³, Gioia Persuitte² and Joel M. Kremer⁴, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴The Albany Medical College, Albany, NY
Background/Purpose: Clinical studies have demonstrated the superior efficacy of tocilizumab monotherapy (TCZ mono) to tumor necrosis factor inhibitor (TNFi) monotherapy and the comparable efficacy of…
Abstract Number: 1603 • 2016 ACR/ARHP Annual Meeting
Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis
Laura Cappelli¹, J. Lynn Palmer² and Clifton Bingham III³, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²CORRONA Research Foundation, Phoenix, AZ, ³Johns Hopkins University, Baltimore, MD
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis Background/Purpose: Biologic medications have improved outcomes for patients with rheumatoid arthritis (RA), but little…
Abstract Number: 1636 • 2016 ACR/ARHP Annual Meeting
Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study
Renaud DESBARBIEUX, 59037, CHRU de Lille, Lille, France
Background/Purpose: The advent of biological therapies in rheumatoid arthritis has significantly reduced the activity of rheumatoid arthritis, leading to obtaining a remission in a significant…
Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Maria Hoehle, Rheumatology, Hamburg, Germany
Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
Abstract Number: 2502 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Therapy Reduces Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Isamu Yokoe³, Kaita Sugiyama⁴, Yosuke Nagasawa⁵, Hirotake Inomata⁴, Natsumi Ikumi⁶, Atsuma Nishiwaki⁴, Takamasa Nozaki¹, Noboru Kitamura⁵ and Masami Takei⁵, ¹Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan, ⁴Nihon University School of Medicine, Tokyo, Japan, ⁵Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Shinjuku, Japan
Background/Purpose: Individuals with rheumatoid arthritis (RA) have a two-fold higher risk of sudden death than the healthy age- and sex-matched general population. Although the underlying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].